Pathogenesis of myelofibrosis with myeloid metaplasia

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8520-8530

  Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA2A INTERFERON; ANAGRELIDE; CLADRIBINE; CYTOKINE; ETANERCEPT; FIBROBLAST GROWTH FACTOR; IMIPRAMINE; LENALIDOMIDE; OSTEOPROTEGERIN; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; RI 15777; SEMAXANIB; SURAMIN; THALIDOMIDE DERIVATIVE; TRANSCRIPTION FACTOR GATA 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ARTICLE; CHROMOSOME ANALYSIS; CLINICAL TRIAL; DRUG EFFECT; GENE CONSTRUCT; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; IN VIVO STUDY; MEGAKARYOCYTE; MOLECULAR CLONING; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; OSTEOSCLEROSIS; PRIORITY JOURNAL; ANIMAL; BONE MARROW; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BONE MARROW; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA;

EID: 30844443469     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.9316     Document Type: Article

References (201)

1. Heuck G: Zwei Falle von Leukamie mit eigenthumlichem Blut- resp: Knochenmarksbefund. Arch Pathol Anat Physiol Virchows 78:475-496, 1879
2. Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 6:372-375, 1951
3. Passamonti F, Malabarba L, Orlandi E, et al: Polycythemia vera in young patients: A study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 88:13-18, 2003
4. Cervantes F, Alvarez-Larran A, Talarn C, et al: Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 118:786-790, 2002
5. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265, 2000
6. Mesa RA, Hanson CA, Rajkumar SV, et al: Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96:3374-3380, 2000
7. Mesa RA, Silverstein MN, Jacobsen SJ, et al: Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County study, 1976-1995. Am J Hematol 61:10-15, 1999
8. Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 88:1013-1018, 1996
9. Cervantes F, Pereira A, Esteve J, et al: Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635-640, 1997
10. Rupoli S, Da Lio L, Sisti S, et al: Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 68:205-212, 1994
11. Okamura T, Kinukawa N, Niho Y, et al: Primary chronic myelofibrosis: Clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73:194-198, 2001
12. Tefferi A: Treatment approaches in myelofibrosis with myeloid metaplasia: The old and the new. Semin Hematol 40:18-21, 2003
13. Deeg HJ, Gooley TA, Flowers ME, et al: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102:3912-3918, 2003
14. Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189-194, 1978
15. Groopman JE: The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 92:857-858, 1980
16. Kim HJ, Tisdale JF, Wu T, et al: Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in non-human primates. Blood 96:1-8, 2000
17. Reeder TL, Bailey RJ, Dewald GW, et al: Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood 101:1981-1983, 2003
18. Beutler E, Collins Z, Irwin LE: Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors. N Engl J Med 276:389-391, 1967
19. Goto T, Monk M: Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev 62:362-378, 1998
20. Vogelstein B, Fearon ER, Hamilton SR, et al: Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science 227:642-645, 1985
21. Prchal JT, Guan YL: A novel clonality assay based on transcriptional analysis of the active X chromosome. Stem Cells 11:62-65, 1993 (suppl 1)
22. Gilliland DG, Blanchard KL, Levy J, et al: Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A 88:6848-6852, 1991
23. Fialkow PJ, Faguet GB, Jacobson RJ, et al: Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58:916-919, 1981
24. Adamson JW, Fialkow PJ, Murphy S, et al: Polycythemia vera: Stem-cell and probable clonal origin of the disease. N Engl J Med 295:913-916, 1976
25. Elkassar N, Hetet G, Briere J, et al: Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets. Blood 89:128-134, 1997
26. Kreipe H, Jaquet K, Felgner J, et al: Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 78:1814-1817, 1991
27. Engel W, Merker H, Schneider G, et al: Clonal occurrence of a chromosome Dq-in myelosclerosis with myeloid metaplasia. Humangenetik 6:335-337, 1968
28. Kahn A, Bernard JF, Cottreau D, et al: Gd(-) Abrami: A deficient G-6PD variant with hemizygous expression in blood cells of a woman with primary myelofibrosis. Humangenetik 30:41-46, 1975
29. Anger B, Janssen JW, Schrezenmeier H, et al: Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia 4:258-261, 1990
30. Tsukamoto N, Morita K, Maehara T, et al: Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: Demonstration of heterogeneity in lineage involvement. Br J Haematol 86:253-258, 1994
31. Ruutu T, Partanen S, Knuutila S: Clonal karyotype abnormalities in erythroid and granulocyte-monocyte precursors in polycythaemia vera and myelofibrosis. Scand J Haematol 31:253-256, 1983
32. Sugiyama H, Ichiba S, Okuno Y, et al: Cytogenetic evidence for a clonal disorder involving CFU-GEMM, BFU-E and CFU-C in patients with myeloproliferative disorders. Nippon Ketsueki Gakkai Zasshi 52:1022-1032, 1989
33. Greenberg BR, Woo L, Veomett IC, et al: Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br J Haematol 66:487-490, 1987
34. Wang JC, Lang HD, Lichter S, et al: Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 80:184-188, 1992
35. Buschle M, Janssen JW, Drexler H, et al: Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: Clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 2:658-660, 1988
36. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. J Natl Cancer Inst 25:85, 1960
37. Larson RA, Kondo K, Vardiman JW, et al: Evidence for a 15:17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:827-841, 1984
38. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830, 1990
39. de The H, Chomienne C, Lanotte M, et al: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558-561, 1990
40. Lowenberg B, Hagemeijer A, Swart K: Karyotypically distinct subpopulations in acute leukemia with specific growth requirements. Blood 59:641-645, 1982
41. Tamura S, Kanamaru A, Takemoto Y, et al: Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow. Br J Haematol 84:219-226, 1993
42. Nowell P, Jensen J, Gardner F, et al: Chromosome studies in "preleukemia". III. Myelofibrosis. Cancer 38:1873-1881, 1976
43. Hsu LY, Pinchiaroli D, Gilbert HS, et al: Partial trisomy of the long arm of chromosome 1 in myelofibrosis and polycythemia vera. Am J Hematol 2:375-383, 1977
44. Whang-Peng J, Knutsen T, Chang P, et al: Cytogenetic studies in patients with myelofibrosis and myeloid metaplasia. Leuk Res 2:41-56, 1978
45. Nowell P, Finan J: Chromosome studies in preleukemic states, IV. Myeloproliferative versus cytopenic disorders. Cancer 42:2254-2261, 1978
46. Geraedts JP, den Ottolander GJ, Ploem JE, et al: An identical translocation between chromosome 1 and 7 in three patients with myelofibrosis and myeloid metaplasia. Br J Haematol 44:569-575, 1980
47. Pakkala A, Ruutu T, Partanen S, et al: Peripheral blood cells in the study of chromosome aberrations of patients with chronic myeloid leukaemia or myelofibrosis. Acta Haematol 70:264-268, 1983
48. Borgstrom GH, Knuutila S, Ruutu T, et al: Abnormalities of chromosome 13 in myelofibrosis. Scand J Haematol 33:15-21, 1984
49. Miller JB, Testa JR, Lindgren V, et al: The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 55:582-591, 1985
50. Castoldi G, Cuneo A, Tomasi P, et al: Chromosome abnormalities in myelofibrosis. Acta Haematol 78:104-108, 1987 (suppl 1)
51. Smadja N, Krulik M, de Gramont A, et al: Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia. Cancer Genet Cytogenet 24:151-158, 1987
52. Demory JL, Dupriez B, Fenaux P, et al: Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: A report on 47 cases. Blood 72:855-859, 1988
53. Emilia G, Temperani P, Ferrari S, et al: Cytogenetic and molecular studies in primary myelofibrosis. Cancer Genet Cytogenet 38:101-113, 1989
54. Donti E, Tabilio A, Bocchini F, et al: Partial trisomy 1q in idiopathic myelofibrosis. Leuk Res 14:1035-1040, 1990
55. Mertens F, Johansson B, Heim S, et al: Karyotypic patterns in chronic myeloproliferative disorders: Report on 74 cases and review of the literature. Leukemia 5:214-220, 1991
56. Werner M, Nolte M, Kaloutsi V, et al: Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders. Lab Invest 72:405-410, 1995
57. Reilly JT, Snowden JA, Spearing RL, et al: Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. Br J Haematol 98:96-102, 1997
58. Rege-Cambrin G, Mecucci C, Tricot G, et al: A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 25:233-245, 1987
59. Swolin B, Weinfeld A, Westin J: A prospective long-term Cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 72:386-395, 1988
60. Diez-Martin JL, Graham DL, Petitt RM, et al: Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 66:287-299, 1991
61. MacDonald DH, Lahiri D, Chase A, et al: A case of myelofibrosis with a t(4;13)(q25;q12): Evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders. Br J Haematol 105:771-774, 1999
62. Emilia G, Sacchi S, Temperani P, et al: Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma 9:423-426, 1993
63. Tefferi A, Mesa RA, Schroeder G, et al: Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 113:763-771, 2001
64. Tefferi A, Meyer RG, Wyatt WA, et al: Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 115:316-319, 2001
65. Pasture C, Nomdedeu J, Volpe G, et al: Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosomes Cancer 14:106-111, 1995
66. Tricot G, Barlogie B, Jagannath S, et al: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256, 1995
67. Fonseca R, Oken MM, Harrington D, et al: Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15:981-986, 2001
68. Fonseca R, Harrington D, Oken MM, et al: Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 62:715-720, 2002
69. Bench AJ, Nacheva EP, Hood TL, et al: Chromosome 20 deletions in myeloid malignancies: Reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes-UK Cancer Cytogenetics Group (UKCCG). Oncogene 19:3902-3913, 2000
70. Giraudier S, Chagraoui H, Komura E, et al: Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 100:2932-2940, 2002
71. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144-1148, 2005
72. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397, 2005
73. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061, 2005
74. Abu-Duhier FM, Goodeve AC, Care RS, et al: Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. Br J Haematol 120:464-470, 2003
75. Pardanani A, Reeder TL, Kimlinger TK, et al: Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 27:739-742, 2003
76. Thiagalingam S, Foy RL, Cheng KH, et al: Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: Molecular basis of its occurrence. Curr Opin Oncol 14:65-72, 2002
77. Jones LC, Tefferi A, Idos GE, et al: RAR-beta2 is a candidate tumor suppressor gene in rnyelofibrosis with myeloid metaplasia. Oncogene 23:7846-7853, 2004
78. Villar-Garea A, Esteller M: DNA demethylating agents and chromatin-remodeling drugs: Which, how and why? Curr Drug Metab 4:11-31, 2003
79. Kurie JM, Lotan R, Lee JJ, et al: Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: Results from a randomized placebo-controlled trial. J Natl Cancer Inst 95:206-214, 2003
80. Tefferi A, Bolander ME, Ansell SM, et al: Primer on medical genomics: Part III. Microarray experiments and data analysis. Mayo Clin Proc 77:927-940, 2002
81. Ebert BL, Golub TR: Genomic approaches to hematologic malignancies. Blood 104:923-932, 2004
82. Jones LC, Tefferi A, Wachsman W, et al: Detection of aberrant signaling pathways in CD34+cells from patients with myelofibrosis with myeloid metaplasia using oligonucleotide microarrays. Blood 98:626a-626a, 2001
83. Zajac-Kaye M: Myc oncogene: A key component in cell cycle regulation and its implication for lung cancer. Lung Cancer 34:S43-S46, 2001 (suppl 2)
84. Schrader JW: Biological effects of myeloid growth factors. Baillieres Clin Haematol 5:509-531, 1992
85. Di Raimondo F, Palumbo GA, Molica S, et al: Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 106:177-183, 2001
86. Miyazato A, Ueno S, Ohmine K, et al: Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98:422-427, 2001
87. Denhardt DT, Guo X: Osteopontin: A protein with diverse functions. Faseb J 7:1475-1482, 1993
88. Schmitt JM, Hwang K, Winn SR, et al: Bone morphogenetic proteins: An update on basic biology and clinical relevance. J Orthop Res 17:269-278, 1999
89. Taksin AL, Couedic JPL, Dusanter-Fourt I, et al: Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by MpI-L. Blood 93:125-139, 1999
90. Ozaki S, Kosaka M, Ozaki K, et al: Thrombopoietin-responsive essential thrombocythaemia with myelofibrosis. Br J Haematol 97:449-452, 1997
91. Li Y, Hetet G, Maurer AM, et al: Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br J Haematol 87:471-476, 1994
92. Kobayashi S, Teramura M, Hoshino S, et al: Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Br J Haematol 83:539-544, 1993
93. Han ZC, Briere J, Nedellec G, et al: Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis. Eur J Haematol 40:130-135, 1988
94. Juvonen E: Megakaryocyte colony formation in chronic myeloid leukemia and myelofibrosis. Leuk Res 12:751-756, 1988
95. Lutton JD, Levere RD: Endogenous erythroid colony formation by peripheral blood mononuclear cells from patients with myelofibrosis and polycythemia vera. Acta Haematol 62:94-99, 1979
96. Juvonen E, Partanen S, Ruutu T: Colony formation by megakaryocytic progenitors in essential thrombocythaemia. Br J Haematol 66:161-164, 1987
97. Prchal JF, Axelrad AA: Letter: Bonemarrow responses in polycythemia vera. N Engl J Med 290:1382, 1974
98. Fisher MJ, Prchal JF, Prchal JT, et al: Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 84:1982-1991, 1994
99. Juvonen E, Partanen S, Ikkala E, et al: Megakaryocytic colony formation in polycythaemia vera and secondary erythrocytosis. Br J Haematol 69:441-444, 1988
100. Juvonen E, Ikkala E, Oksanen K, et al: Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications. Br J Haematol 83:192-197, 1993
101. Battegay EJ, Thomssen C, Nissen C, et al: Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders. Eur J Haematol 42:321-326, 1989
102. Florensa L, Besses C, Woessner S, et al: Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia. Leukemia 9:271-273, 1995
103. Reid CD: The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Rev 1:133-140, 1987
104. Hess G, Rose P, Gamm H, et al: Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 88:794-802, 1994
105. Asimakopoulos FA, Hinshelwood S, Gilbert JGR, et al: The gene encoding hematopoietic cell phosphatase (Shp-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene 14:1215-1222, 1997
106. Komura E, Chagraoui H, Mansat de Mas V, et al: Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: Possible relationship with FKBP51 overexpression. Exp Hematol 31:622-630, 2003
107. Bock O, Neusch M, Busche G, et al: Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis. Eur J Haematol 72:239-244, 2004
108. Briard D, Brouty-Boye D, Giron-Michel J, et al: Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol 106:201-212, 2003
109. Steelman LS, Pohnert SC, Shelton JG, et al: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218, 2004
110. Boudny V, Kovarik J: JAK/STAT signaling pathways and cancer: Janus kinases/signal transducers and activators of transcription. Neoplasma 49:349-355, 2002
111. Steunou V, Le Bousse-Kerdiles MC, Colin-Micouin A, et al: Altered transcription of the stem cell leukemia gene in myelofibrosis with myeloid metaplasia. Leukemia 17:1998-2006, 2003
112. Harrison CN, Gale RE, Pezella F, et al: Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br J Haematol 107:139-147, 1999
113. Yoon SY, Li CY, Tefferi A: Megakaryocyte C-MpI expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: Immunoperoxidase staining patterns and clinical correlates. Eur J Haematol 65:170-174, 2000
114. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 338:572-580, 1998
115. Horikawa Y, Matsumura I, Hashimoto K, et al: Markedly reduced expression of platelet C-MpI receptor in essential thrombocythemia. Blood 90:4031-4038, 1997
116. Elliot MA, Yoon SY, Kao P, et al: Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte C-MpI with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia. Eur J Haematol 68:175-179, 2002
117. Tefferi A: The pathogenesis of chronic myeloproliferative diseases. Int J Hematol 73:170-176, 2001
118. Castro-Malaspina H, Gay RE, Jhanwar SC, et al: Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. Blood 59:1046-1054, 1982
119. Castro-Malaspina H, Rabellino EM, Yen A, et al: Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 57:781-787, 1981
120. Rameshwar P, Denny TN, Stein D, et al: Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: Potential role for interleukin-1 and TGF-beta. J Immunol 153:2819-2830, 1994
121. Terui T, Niitsu Y, Mahara K, et al: The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 75:1540-1548, 1990
122. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al: Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. BrJ Haematol 88:9-16, 1994
123. Martyre MC, Magdelenat H, Bryckaert MC, et al: Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 77:80-86, 1991
124. Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al: Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 88:4534-4546, 1996
125. Le Bousse-Kerdiles MC, Martyre MC, French Irno IM: Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris) 49:153-157, 2001
126. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al: Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 97:441-448, 1997
127. Di Raimondo F, Azzaro MP, Palumbo GA, et al: Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 15:976-980, 2001
128. Wang JC, Novetsky A, Chen C, et al: Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis. BrJ Haematol 119:709-712, 2002
129. Jensen MK, Holten-Andersen MN, Riisbro R, et al: Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. Eur J Haematol 71:377-384, 2003
130. Katoh O, Kimura A, Itoh T, et al: Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 35:145-150, 1990
131. Schmitt A, Jouault H, Guichard J, et al: Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 96:1342-1347, 2000
132. Centurione L, Di Baldassarre A, Zingariello M, et al: Increased and pathological emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1 low mice. Blood 104:3573-3580, 2004
133. Pelus LM, Bian H, King AG, et al: Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRO-beta/CXCL2 and GRO-betaT/CXCL2- delta-4. Blood 103:110-119, 2004
134. Barosi G, Viarengo G, Pecci A, et al: Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98:3249-3255, 2001
135. Xu M, Bruno E, Chao J, et al: The constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 105:4508-4515, 2005
136. Chagraoui H, Komura E, Tulliez M, et al: Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 100:3495-3503, 2002
137. Yanagida M, Ide Y, Imai A, et al: The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 99:739-745, 1997
138. Yan XQ, Lacey D, Fletcher F, et al: Chronic exposure to retroviral vector encoded MGDF (mpI-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 86:4025-4033, 1995
139. Yan XQ, Lacey D, Hill D, et al: A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpI ligand): Reversal of disease by bone marrow transplantation. Blood 88:402-409, 1996
140. Villeval JL, Cohensolal K, Tulliez M, et al: High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90:4369-4383, 1997
141. Vannucchi AM, Bianchi L, Cellai C, et al: Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 100:1123-1132, 2002
142. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 86:419-431, 1995
143. Vyas P, AuIt K, Jackson CW, et al: Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 93:2867-2875, 1999
144. Zhou W, Toombs CF, Zou T, et al: Transgenic mice overexpressing human C-MpI ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment. Blood 89:1551-1559, 1997
145. Kakumitsu H, Kamezaki K, Shimoda K, et al: Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res 29:761-769, 2005
146. Frey BM, Rafii S, Teterson M, et al: Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: Insights into the pathophysiology of osteomyelofibrosis. J Immunol 160:691-699, 1998
147. Abina MA, Tulliez M, Lacout C, et al: Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: Risk of sustained expression inducing myelofibrosis due to immunosuppression. Gene Ther 5:497-506, 1998
148. Ulich TR, Delcastillo J, Senaldi G, et al: Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 87:5006-5015, 1996
149. Shehata M, Schwarzmeier JD, Hilgarth M, et al: TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest 113:676-685, 2004
150. Chagraoui H, Tulliez M, Smayra T, et al: Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 101:2983-2989, 2003
151. Vannucchi A, Bianchi L, Laurenzana A, et al: In vivo treatment with thrombopoietin corrects the thrombocytopenia and does not accelerate the progression of myelofibrosis in GATA-1 low mice. Exp Hematol 31:186-187, 2003 (abstr)
152. Vannucchi A, Bianchi L, Paoletti F, et al: Impaired GATA-1 expression and myelofibrosis in an animal model. Pathol Biol 52:275-279, 2004
153. Tefferi A, Elliot MA, Yoon SY, et al: Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 97:1896, 2001
154. Tefferi A, Silverstein MN, Li CY: 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 99:352-357, 1997
155. Faoro LN, Tefferi A, Mesa RA: Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 74:117-120, 2005
156. Yoon SY, Li CY, Mesa RA, et al: Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 106:682-688, 1999
157. Tefferi A, Silverstein MN, Plumhoff EA, et al: Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst 85:1520-1522, 1993
158. Mesa RA, Tefferi A, Elliott MA, et al: A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 114:111-113, 2001
159. Tefferi A, Mesa RA, Gray LA, et al: Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 99:3854-3856, 2002
160. Mesa RA, Elliott MA, Schroeder G, et al: Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 79:883-889, 2004
161. Mesa RA, Steensma DP, Pardanani A, et al: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534-2541, 2003
162. Tefferi A, Elliot MA: Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 96:4007, 2000
163. Elliott MA, Mesa RA, Li CY, et al: Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 117:288-296, 2002
164. Steensma DP, Mesa RA, Li CY, et al: Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study. Blood 99:2252-2254, 2002
165. Dredge K, Marriott JB, Macdonald CD, et al: Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172, 2002
166. Corral LG, Haslett PA, Muller GW, et al: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380-386, 1999
167. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005
168. Zhang B, Prendergast GC, Fenton RG: Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 62:450-458, 2002
169. Cortes J, Albitar M, Thomas D, et al: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101:1692-1697, 2003
170. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417-421, 2004
171. Giles FJ, Cooper MA, Silverman L, et al: Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer 97:1920-1928, 2003
172. Smolich BD, Yuen HA, West KA, et al: The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97:1413-1421, 2001
173. Giles FJ, List AF, Roboz GJ, et al: Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaplasia. Blood 102:922a-923a, 2003
174. Butzal M, Loges S, Schweizer M, et al: Rapamycm inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 300:65-71, 2004
175. Shegogue D, Trojanowska M: Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 279:23166-23175, 2004
176. Gomez-Cambronero J: Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett 550:94-100, 2003
177. Hu X, Zuckerman KS: Transforming growth factor: Signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res 10:67-74, 2001
178. Chujo S, Shirasaki F, Kawara S, et al: Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 203:447-456, 2005
179. Leask A, Holmes A, Black CM, et al: Connective tissue growth factor gene
180. Mageto Y, Flaherty K, Brown K, et al: Safety and tolerability of human monoclonal antibody FG-3019, anti-connective tissue growth factor, in patients with idiopathic pulmonary fibrosis. Chest 126:773Sa, 2004 (abstr)
181. Uhl M, Aulwurm S, Wischhusen J, et al: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954-7961, 2004
182. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al: SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3:737-745, 2004
183. Flanders KC: Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85:47-64, 2004
184. Long J, Matsuura I, He D, et al: Repression of Smad transcriptional activity by PIASy, an inhibitor of activated STAT. Proc Natl Acad Sci U S A 100:9791-9796, 2003
185. Ugo V, Marzac C, Teyssandier I, et al: Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 32:179-187, 2004
186. Zupanska B, Szmigielski S, Litwin J, et al: Cytoenzymatic changes in the course of experimental osteomyelosclerosis in rats. Arch Immunol Ther Exp (Warsz) 14:356-362, 1966
187. Stodtmeister R, Becker H, Cronkite EP, et al: Experimental bone marrow fibrosis in rats following sublethal whole-body x-ray irradiation and bone marrow transfusions as a model of human myelofibrosis [in German]. Schweiz Med Wochenschr 98:1671-1673, 1968
188. Van Gorp LH, Swaen GJ: Myelofibrosis in rats experimentally infected with a murine leukaemia virus. J Pathol 97:235-240, 1969
189. Takacsi-Nagy L, Juhasz J: Experimental myelosclerosis. Haematologia (Budap) 5:283-291, 1971
190. Stodtmeister R, Fliedner TM: Morphological aspects of myelofibrosis, observed in rats following sublethal whole body irradiation and subsequent allogeneic bone marrow cell transfusion. Folia Haematol Int Mag Klin Morphol Blutforsch 100:23-50, 1973
191. Hunstein W: Experimental myelofibrosis. Clin Haematol 4:457-478, 1975
192. Ebbe S: Experimental and clinical megakaryocytopoiesis. Clin Haematol 8:371-394, 1979
193. Ruddle NH, Li CB, Horne WC, et al: Mice transgenic for HTLV-I LTR-tax exhibit tax expression in bone, skeletal alterations, and high bone turnover. Virology 197:196-204, 1993
194. Harrison CN, Gale RE, Wiestner AC, et al: The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol 102:1341-1343, 1998
195. Kiladjian JJ, Elkassar N, Hetet G, et al: Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia 11:1821-1826, 1997
196. Martyre MC, Steunou V, LeBousse-Kerdiles MC, et al: Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis. Blood 101:5087-5088; author reply 5088-5089, 2003
197. Gandini D, Allen AJ, Nash MJ, et al: No mutations in the gata-1 gene detected in patients with acquired essential thrombocythemia. Haematologica 89:613-615, 2004
198. Fisher C, Steensma D, Janmohamed R, et al: Absence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis. Br J Haematol 126:750-752, 2004
199. Najfeld V, Montella L, Scalise A, et al: Exploring polycythaemia vera with fluorescence in situ hybridization: Additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 119:558-566, 2002
200. Steensma DP, Tefferi A: Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 108:55-65, 2002
201. Pfeilstocker M, Reisner R, Nosslinger T, et al: Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106:455-463, 1999